Paul Everson

Glioma treatment using Checkpoint inhibition + CAR looks promising!

CD133 specific CAR-macrophages created in situ using NanoPorter hydrogel in combination with CD47 checkpoint blocking antibody improves post operative Glioblastoma survival in a humanized mouse model “Intracavity generation of glioma stem cell–specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy” Chen Chen, Xinyi Jiang, et al. Science Translational Medicine 14: 656 DOI: 10.1126/scitranslmed.abn1128 CD47 […]

Glioma treatment using Checkpoint inhibition + CAR looks promising! Read More »

Emerging importance of Siglecs in assisting tumor evasion of immune surveillance

Siglecs and their ligands are expressed by many tumors, and can serve to down-regulate immune response. REVIEW article: “The intriguing roles of Siglec family members in the tumor microenvironment” Kui-Ying Jiang, Ling Wang, et al. (2022) Biomarker Research 10: 22 PMID: 35418152 “Molecular Mechanism of Tumor Cell Immune Escape Mediated by CD24/Siglec-10” Shan-Shan Yin, Feng-Hou Gao

Emerging importance of Siglecs in assisting tumor evasion of immune surveillance Read More »

Phase I Clinical Trial of Vaxinia Oncolytic Virus; “the holy grail of cancer therapeutics”?

CF33-hNIS, a modified vaccinia (small pox) virus will be tested by IV or Intratumoral injection, with or without PD-1 inhibitor, pembrolizumab in patients with advanced or metastaic solid tumors. Link to Medical News Today Article Link to Clinical Trial Link to a Background article Ancell human PD-1 related Research Products CD279(PD-1) CD274 (PD-L1) CD273 (PD-L2)

Phase I Clinical Trial of Vaxinia Oncolytic Virus; “the holy grail of cancer therapeutics”? Read More »

ANC28.1 mAb as a stimulating agent in a Cytokine Release Assay for assessment of preclinical safety

“Development of a flow cytometry-based potency assay for prediction of cytokine storms induced by biosimilar monoclonal antibodies” Natasha Helleberg Madsen, Monika Gad, Jesper Larsen. (Feb 5, 2022) J Immunol Methods 502: 113231. https://doi.org/10.10 PBMC were stimulated with immobilized ANC28.1, CD28.1 and muromonab CD3. Assessed Cytokines and levels of Activation molecules by flow could determine the

ANC28.1 mAb as a stimulating agent in a Cytokine Release Assay for assessment of preclinical safety Read More »

Ancell reagents and personnel involved in a new SARS-Co-V2 breast milk antibody study

“Increase in SARS-CoV-2 RBD-specific IgA and IgG Antibodies in Breast Milk from Lactating Women Following the COVID-19 Booster Vaccination” Andrea M Henle MedRxiv (Feb 24, 2022 Pre print) doi: https://doi.org/10.1101/2022.02.23.22271414 Related Ancell products: anti-human IgA monoclonal antibody anti-human IgG monoclonal antibody Recombinant SARS-CO-V2-RBD-His protein #581-820 (Inquire)

Ancell reagents and personnel involved in a new SARS-Co-V2 breast milk antibody study Read More »

Exosomes increase PD-L1 expression and induce tolerance to NIMA

A University of WI Madison research group used Ancell antibodies to analyze exosomes involved in the induction of tolerance to non-inherited maternal antigens(NIMA). This could have implications for allogeneic graft tolerance./ “Cross-Decoration of Dendritic Cells by Non-Inherited Maternal Antigen-Containing Extracellular Vesicles: Potential Mechanism for PD-L1-Based Tolerance in Cord Blood and Organ Transplantation”Diego A. Lema, A

Exosomes increase PD-L1 expression and induce tolerance to NIMA Read More »